Telmisartan
- Generic Name
- Telmisartan
- Brand Names
- Actelsar Hct, Micardis, Micardis-hct, Pritor, Twynsta, Tolura, Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG), Telmisartan Teva Pharma, Telmisartan Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C33H30N4O2
- CAS Number
- 144701-48-4
- Unique Ingredient Identifier
- U5SYW473RQ
- Background
Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arter...
- Indication
Used alone or in combination with other classes of antihypertensives for the treatment of hypertension. Also used in the treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes mellitus, as well as the treatment of congestive heart failure (only in patients who cannot tolerate ACE inhibitors).
- Associated Conditions
- Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hypertension
- Associated Therapies
- -
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 583
- Registration Number
- NCT00153049
- Locations
- 🇯🇵
Boehringer Ingelheim Investigational Site, Taya-gun, Gunma, Japan
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 31546
- Registration Number
- NCT00153101
- Locations
- 🇺🇸
502.373.0247 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸502.373.0177 Boehringer Ingelheim Investigational Site, Tuscon, Arizona, United States
🇦🇺502.373.0529 Launceston General Hospital, Launceston, Tasmania, Australia
Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Failed in Telmisartan 80 mg
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 345
- Registration Number
- NCT00146341
- Locations
- 🇨🇳
Ruijin Hospital, School of Medicine, Shanghai, China
🇨🇳No. 1 Hosp Affiliated to Med College, Zhejiang Province, China
🇨🇳Beijing Tiantan Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.